Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2026)
Monopar Therapeutics (MNPR) posted Profit After Tax of -$3.5 million for Q3 2025, down 42.79% sequentially from -$2.5 million in Q2 2025, and down 168.61% YoY from $5.1 million in Q3 2024.
Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported Profit After Tax for 9 years, with the latest figure at -$3.5 million in Q3 2025.
- Quarterly Profit After Tax fell 168.61% year-over-year to -$3.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$9.9 million (down 49.39% YoY) and the FY2025 annual result came in at -$13.7 million, up 11.45% from the prior year.
- Profit After Tax declined to -$3.5 million in Q3 2025 per MNPR's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$57.0 in Q2 2021 and troughed at -$3.5 million in Q3 2025.
- A 5-year average of -$2.2 million and a median of -$2.4 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2021 and 2022: Profit After Tax surged 100.0% in 2021, then plunged 4847147.37% in 2022.
- Over 5 years, Profit After Tax stood at -$2.7 million in 2021, then dropped by 7.68% to -$2.9 million in 2022, then jumped by 32.15% to -$2.0 million in 2023, then soared by 33.35% to -$1.3 million in 2024, then tumbled by 168.61% to -$3.5 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$3.5 million, -$2.5 million, and -$2.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.32 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.64 Mn |
| Sep 30, 2023 | -1.96 Mn |
| Jun 30, 2023 | -2.20 Mn |
| Mar 31, 2023 | -2.43 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -2.37 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -57.00 |
| Mar 31, 2021 | -1.88 Mn |
| Dec 31, 2020 | -2.13 Mn |
| Sep 30, 2020 | -1.64 Mn |